Skip to main content

Month: September 2020

Hexagon Composites ASA: Save the date – Virtual Capital Markets Day 2020

Hexagon Composites will host a virtual Capital Markets Day on Tuesday 17 November 2020, from 09:00-12:00 CET.Topic: The future of mobility – how we are replacing diesel through our g- and e-mobility solutions.Agenda and details on how to register to follow.Karen Romer, SVP Communications, Hexagon CompositesTelephone: +47 950 74 950 | karen.romer@hexagongroup.comDavid Bandele, CFO, Hexagon CompositesTelephone: +47 920 91 483 |david.bandele@hexagongroup.comAbout Hexagon Composites ASAHexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility, industrial and consumer applications.Learn more at www.hexagongroup.com and follow @HexagonASA on Twitter and LinkedIn

Continue reading

Global Wave and Tidal Energy Market to Gain from Increasing Investments by Private and Public Sectors, says Fortune Business Insights

Pune, Sept. 22, 2020 (GLOBE NEWSWIRE) — A rise in the investments by public and private sectors on the field of renewable energy resources is one of the driving forces of the global wave and tidal energy market. According to a report by Fortune Business Insights, titled, “Wave and Tidal Energy Market Size, Share and Global Trend by Type (Wave Energy, Tidal Energy), by Technology (Tidal Stream Generator, Pendulor Device, Oscillating Water Columns, Barrage, Others), by End User (Residential, Commercial, Industrial), and Geography Forecast till 2026,” a rise in the awareness regarding environmental hazards due to the emission of carbon dioxide from burning fossil fuels is projected to boost the global wave and tidal energy market during the forecast period. Also, an increasing exhausting of fossil fuels across the globe is anticipated...

Continue reading

Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

Bagsværd, Denmark, 22 September 2020 – Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020.The first showed that switching to insulin icodec from other basal insulins using two different switch approaches was efficacious and well-tolerated compared to once-daily insulin glargine U100 and the switching approaches were without an increased risk of clinically significant or severe hypoglycaemic episodes compared to once-daily insulin glargine U100.1 This 16-week phase 2 clinical trial involved 154 adults with type 2 diabetes inadequately controlled with oral antidiabetic drugs and once/twice-daily basal insulin  randomised to once-weekly...

Continue reading

Ehave, Inc. Launches Premier Psychedelic Retreat Centers Partnership and MyLifeID Card Giveaway

MIAMI, Sept. 22, 2020 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today plans to offer access to two premier psilocybin-guided wellness retreats through its wholly owned subsidiary, Mycotopia Therapy which will act as booking site for the partner retreat centers. The retreats will be located in Jamaica www.mycomeditations.com and Amsterdam www.psychedelicinsights.com. Both of the premier psilocybin-guided wellness retreats will be supervised by highly qualified medical professionals. The primary focus of the retreats will be to serve as a means of improving the mental health of individuals suffering from anxiety, OCD, treatment-resistant depression, addiction, and anxiety and depression related to...

Continue reading

Blink Sells or Deploys 539 EV Charging Stations Across 24 States and 4 Countries During Summer Covid-19 Lockdown

New Equipment Installations Expand the Company’s Footprint in Major and Emerging EV MarketsMiami Beach, FL, Sept. 22, 2020 (GLOBE NEWSWIRE) — Blink Charging Co. (Nasdaq: BLNK, BLNKW) (“Blink” or the “Company”), a leading owner and operator of electric vehicle (EV) charging equipment and services, today announced that it has sold or deployed 539 EV charging stations in the United States and internationally during the summer Covid-19 lockdowns of June, July, and August 2020. These numbers represent a nearly 100% increase over the same three-month period in 2019, further expanding Blink’s presence across key markets experiencing significant growth in EV adoption.In the United States 300 charging stations were sold or deployed commercially including 178 new level 2 IQ 200 units along with 2 DC fast charging units. 120 of the EV...

Continue reading

Sanatana Appoints New Director

VANCOUVER, British Columbia, Sept. 22, 2020 (GLOBE NEWSWIRE) — Sanatana Resources Inc. (“Sanatana” or the “Company“: TSX-V: STA) is pleased to announce the appointment of Mr. Anthony Dutton to its board of directors as a non-executive director.Mr. Dutton is a seasoned business executive and entrepreneur with a successful track record as an early stage investor and business founder. He was most recently co-founder, CEO and director of Cannex Capital, a pioneering US cannabis company, before its acquisition of 4Front Holdings Ltd. to create 4Front Ventures (CSE:FFNT), a large multi-state cannabis operator. Prior to Cannex, he was co-founder, CEO and director of IBC Advanced Alloys (TSX.V:IB), a manufacturer of high-performance alloys serving advanced manufacturing and aerospace contractors globally. He currently...

Continue reading

DSS Reiterates Plans for Impact BioMedical Share Dividend

ROCHESTER, N.Y., Sept. 22, 2020 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, reiterates its plans for its previously announced Impact BioMedical share dividend.The first tranche of the two-part special share dividend was announced in August 2020, and DSS shareholders of record as of the record date of 5:00 p.m. ET on September 7, 2020 (“Record Date”) earned a bonus of two shares of Impact BioMedical (“Bonus Shares”) for every one share of DSS common stock held as of the Record Date. Shareholders are not required to hold their DSS shares beyond the Record Date to receive the Bonus Shares. The Bonus...

Continue reading

SANUWAVE Health Hosts Symposium on dermaPACE at Wounds Canada Virtual Conference

World Renowned Wound Care Experts to Lead Discussion on Role of dermaPACE in the Treatment of Chronic WoundsSUWANEE, GA, Sept. 22, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — SANUWAVE Health, Inc. (OTCQB: SNWV), whose focus is the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin, musculoskeletal tissue and vascular structures, announced today that the Company is sponsoring a dermaPACE® educational symposium at the upcoming Wounds Canada Virtual Conference taking place October 14 – 18, 2020.  The educational symposium entitled, “Innovative Energy Transfer Medical System: PACE®-Focused Shockwave Technology Facilitates Revascularization and Capillary Perfusion in Chronic Wounds,” will take place on Saturday, October 17, 2020 at 8:00 am EDT....

Continue reading

CloudMD Announces Closing of $20.79 Million Oversubscribed Bought Deal Financing

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that it has closed its previously announced short form prospectus offering, on a bought deal basis (the “Offering“), including the full exercise of the underwriters’ over-allotment option.Pursuant to the Offering, the Company issued a total of 15,065,000 common shares (the “Shares”) at a price of $1.38 per Share for aggregate gross proceeds of $20,789,700. The Offering was led by Canaccord Genuity Corp. and Beacon Securities Limited on behalf of a syndicate of underwriters including Echelon Wealth Partners Inc. and Mackie Research Capital Corporation (collectively,...

Continue reading

In vitro Diagnostics Market is Forecast to Rise at 4.5% CAGR and Reach USD 87.11 Billion by 2026; Launch of Altostar Molecular Diagnostics Workflow by Altona Diagnostics Gmbh Will Support Growth, says Fortune Business Insights

Pune, Sept. 22, 2020 (GLOBE NEWSWIRE) — According to the report, the global in vitro diagnostics market was valued at USD 61.22 Billion in 2018 is predicted to reach USD 87.11 Billion by 2026, exhibiting a CAGR of 4.5% during the forecast period.As per the report published by Fortune Business Insights, the reagents and consumables segment is expected to hold maximum shares in the global-vitro diagnostics market during the forecast period owing to the increasing research and development activities for the diagnosis of chronic diseases. In addition, the escalating demand for self-test and point-of-care devices will subsequently increase the demand for reagents and consumables segment, which, will, in, turn boost the global In vitro Diagnostics Market revenue during the forecast period.The report offers an elaborative overview of the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.